Similar articles

• Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate.

  Beckett RB, Weiss R, Stitzel RE, Cenedella RJ. Beckett RB, et al. Toxicol Appl Pharmacol. 1972 Sep;23(1):42-53. doi: 10.1016/0041-008x(72)90202-5. Toxicol Appl Pharmacol. 1972. PMID: 5071041 No abstract available.
• Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.

  Berman JS, Hiley CR, Wilson AC. Berman JS, et al. Br J Pharmacol. 1983 Mar;78(3):533-41. doi: 10.1111/j.1476-5381.1983.tb08813.x. Br J Pharmacol. 1983. PMID: 6839062 Free PMC article.
• Clofibrate and nafenopin (SU-13437): effects on plasma clearance and tissue distribution of chylomicron triglyceride in the dog.

  Cenedella RJ. Cenedella RJ. Lipids. 1972 Oct;7(10):644-52. doi: 10.1007/BF02533070. Lipids. 1972. PMID: 4635558 No abstract available.
• Possible properties of microbodies (peroxisomes). Microbody proliferation and hypolipidemic drugs.

  Reddy JK. Reddy JK. J Histochem Cytochem. 1973 Nov;21(11):967-71. doi: 10.1177/21.11.967. J Histochem Cytochem. 1973. PMID: 4587529 Review. No abstract available.
• Newer hypolipidemic compounds.

  Kritchevsky D. Kritchevsky D. Adv Exp Med Biol. 1975;63:135-50. doi: 10.1007/978-1-4684-3258-9_9. Adv Exp Med Biol. 1975. PMID: 1106139 Review. No abstract available.